Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (NASDAQ: MASI) is collaborating with Renown Health in Reno, Nevada, to address the COVID-19 surge through the use of Masimo SafetyNet, a remote patient management platform. This technology supports home recovery for COVID-19 patients while enabling clinicians to monitor their conditions remotely. Renown Health employs Masimo's advanced monitoring solutions to enhance patient care and mitigate hospital congestion during the pandemic. Masimo SafetyNet combines noninvasive monitoring tools to ensure timely interventions, ultimately improving patient outcomes and reducing healthcare costs.
Masimo (NASDAQ: MASI) revealed findings from a study presented at Euroanaesthesia 2020, led by Dr. Kumagai at Iwate Medical University. The research demonstrated that Masimo ORi™, or Oxygen Reserve Index, effectively limits postoperative hyperoxia, potentially preventing hypoxia. In a trial involving 50 breast surgery patients, those monitored with ORi had significantly lower arterial oxygen levels post-surgery compared to a control group. However, ORi is currently not available in the U.S. due to the lack of FDA 510(k) clearance.
Masimo (NASDAQ: MASI) presented findings at Euroanaesthesia 2020, revealing that its noninvasive hemoglobin monitoring technology, SpHb, significantly improved outcomes in pediatric patients undergoing major surgeries. The study indicated a reduced rate of postoperative transfusions, shorter ICU stays, and decreased morbidity compared to traditional methods. Key metrics showed a 40% reduction in ICU stay durations and a 43% decrease in postoperative red blood cell transfusions. These results highlight SpHb's potential for better patient care and cost-effectiveness in transfusion management.
Masimo (NASDAQ: MASI) was recognized as one of seven innovators at California Life Sciences Association's Pantheon 2020 for its role in addressing COVID-19 challenges. The company's Masimo SafetyNet platform supports remote patient monitoring, enabling clinicians to track patients' health metrics from home, thus alleviating hospital strain. Mike Guerra from CLSA praised Masimo's adaptability during the pandemic. CEO Joe Kiani acknowledged the frontline healthcare workers' contributions and highlighted the impact of their technology in improving patient outcomes.
Masimo (NASDAQ: MASI) announces participation in the Piper Sandler Virtual Healthcare Conference on December 2, 2020, at 3:30 p.m. ET. The live presentation will be webcast on the Masimo website, with a replay available afterward. Masimo is recognized for its innovative medical monitoring technologies aimed at improving patient outcomes and reducing healthcare costs. Notably, Masimo SET® pulse oximetry is employed in over 100 million patients globally, with advancements enhancing its accuracy under various conditions.
Masimo (NASDAQ: MASI) announced a study published in the Ain-Shams Journal of Anesthesiology, highlighting the effectiveness of its PVi technology for assessing fluid responsiveness in mechanically ventilated patients. Conducted at Ain-Shams University, the study found PVi to be more reliable and continuous compared to dIVC, with significant results showing PVi's reliability (93.75% sensitivity) against an invasive method. These findings support PVi's potential in improving patient care in surgical ICU settings.
Masimo (NASDAQ: MASI) is set to present at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. Eastern Time. Live access to the presentation will be available via webcast on the Masimo website, with a replay offered afterward. Known for its advanced medical monitoring technologies, Masimo’s innovations, such as SET pulse oximetry, have significantly improved patient outcomes and reduced healthcare costs. The company’s products are used globally, impacting over 100 million patients and assisting healthcare professionals in critical care scenarios.
Masimo (NASDAQ: MASI) recently published a study in Blood Transfusion highlighting the advantages of utilizing its SpHb technology within a patient blood management (PBM) program for postoperative cancer patients. The study demonstrated a significant increase in transfusion appropriateness, rising from 38% to 79% with the implementation of SpHb monitoring. Additionally, the average number of red blood cell units transfused per patient declined from 1.8 to 1.3. The researchers emphasize that structured PBM programs can improve transfusion quality and quantity.
Masimo (NASDAQ: MASI) has announced that its wearable, tetherless vital signs monitor, Radius VSM™, has received CE marking and is being launched in select European markets. This versatile device can monitor various physiological parameters, including continuous pulse oximetry and noninvasive blood pressure. Radius VSM features a modular design suited for different patient needs and encourages mobility for faster recovery. It offers wireless communication with bedside monitors and EMR systems, enhancing patient care, especially during COVID-19. CEO Joe Kiani expressed excitement for its European rollout and future global availability.
Masimo (NASDAQ: MASI) reported strong Q3 2020 results, with total revenue reaching $278.1 million, a 21.4% increase from Q3 2019. Product revenue rose by 21.5%, while noninvasive technology shipments surged 150% year-over-year. GAAP net income was $49.4 million ($0.85 per share), compared to $49.1 million ($0.86) in 2019. The company updated its full-year 2020 guidance, projecting total revenue of $1,128.0 million and diluted EPS of $3.77. Masimo cited ongoing investments to address COVID-19 challenges as a key factor in its growth.